StreetInsider.com News Articles

Denali Therapeutics Inc. (DNLI) PT Raised to $36 at Morgan Stanley

Thu, 23 Jul 2026 08:43:09 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $36.00 (from $35.00) while maintaining a Overweight rating.

Denali Therapeutics Inc. (DNLI) PT Raised to $35 at Deutsche Bank

Fri, 17 Jul 2026 07:17:00 -0400

Deutsche Bank analyst David Hoang raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $35.00 (from $31.00) while maintaining a Buy rating.

Denali Therapeutics (DNLI) call put ratio 1.3 calls to 1 put as share price up 2.2%

Mon, 13 Jul 2026 14:20:17 -0400

Denali Therapeutics (NASDAQ: DNLI) 30-day option implied volatility is at 85; compared to its 52-week range of 53 to 118. Call put ratio 1.3 calls to 1 put as share price up 2.2%.

JPMorgan Resumes Denali Therapeutics Inc. (DNLI) at Overweight

Mon, 13 Jul 2026 03:14:33 -0400

JPMorgan analyst Jessica Fye resumes coverage on Denali Therapeutics Inc. (NASDAQ: DNLI) with a Overweight rating and a price target of $29.00.

The analyst comments: “We are moving to an Overweight rating and $29 December 2027 price target for DNLI shares. With the recent approval of Avlayah for Hunter syndrome, DNLI has transitioned to a commercial biotech, and we see the possibility of accelerated approval as soon as YE27 for DNL126 in Sanfillippo type-A (MPS IIIA). Beyond these lead rare disease programs, we see a rich pipeline advancing with multiple readouts over the next 12-18 months including 1) DNL593 for FTD,

JPMorgan Resumes Denali Therapeutics Inc. (DNLI) at Overweight

Mon, 13 Jul 2026 03:14:33 -0400

JPMorgan analyst Jessica Fye resumes coverage on Denali Therapeutics Inc. (NASDAQ: DNLI) with a Overweight rating and a price target of $29.00.

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Ba

Thu, 09 Jul 2026 16:01:00 -0400

Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026
Presentation will highlight recent scientific advances and future opportunities to accelerate discovery and development of medicines for neurodegenerative diseases
Denali is advancing multiple investigational therapies designed to cross blood-brain barrier for Alzheimer’s disease, including DNL628 (OTV:MAPT) targeting tau and DNL921 (ATV:Abeta) targeting amyloid beta

SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that co-founder and Chief Executive Officer Ryan Watts, Ph.D., will deliver the

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Ba

Thu, 09 Jul 2026 16:01:00 -0400

Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026
Presentation will highlight recent scientific advances and future opportunities to accelerate discovery and development of medicines for neurodegenerative diseases
Denali is advancing multiple investigational therapies designed to cross blood-brain barrier for Alzheimer’s disease, including DNL628 (OTV:MAPT) targeting tau and DNL921 (ATV:Abeta) targeting amyloid beta

SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that co-founder and Chief Executive Officer Ryan Watts, Ph.D., will deliver the

Form SCHEDULE 13G/A Denali Therapeutics Inc. Filed by: T. Rowe Price Investment Management, Inc.

Wed, 08 Jul 2026 11:30:00 -0400

si-local-file:///var/storage/secattach/20260708/26746223.html

Form SCHEDULE 13G/A Denali Therapeutics Inc. Filed by: T. Rowe Price Investment Management, Inc.

Wed, 08 Jul 2026 11:30:00 -0400

si-local-file:///var/storage/secattach/20260708/26746223.html

Mon, 22 Jun 2026 09:26:35 -0400

Stifel analyst Paul Mattels reiterated a Buy rating and $41.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI).

The analyst commented, " At our West Coast Bus Tour, we caught up with CEO/Founder Ryan Watts and CCO Katie Peng. Key takeaways from the discussion include: (1) management remains very encouraged by the launch progress of Avlayah in Hunter syndrome, where they've cited meaningful interest/engagement from patients and prescribers, (2) they're confident in the clinical success of DNL126 in Sanfilippo--data/BLA submission expected next year though this is a market that requires building, (3) BIIB080/anti-tau ph2 AD data in July is a big

Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Mon, 22 Jun 2026 09:26:11 -0400

Stifel analyst Paul Mattels reiterated a Buy rating and $41.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI).

Form 8-K Denali Therapeutics Inc. For: Jun 12

Thu, 18 Jun 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260618/26663145.html

Form 8-K Denali Therapeutics Inc. For: Jun 12

Thu, 18 Jun 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260618/26663145.html

Denali Therapeutics to sell priority review voucher for $195M

Thu, 18 Jun 2026 08:00:11 -0400

Denali Therapeutics Inc. (Nasdaq: DNLI) has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $195 million, the company said in a press release.

The U.S. Food and Drug Administration awarded the voucher to Denali following its accelerated approval in March 2026 of AVLAYAH (tividenofusp alfa-eknm), an enzyme replacement therapy for Hunter syndrome, also known as mucopolysaccharidosis type II. Denali describes AVLAYAH as the first FDA-approved medicine designed to cross the blood-brain barrier via transferrin receptor-mediated transport.

The company said proceeds from the sale will support the advancement of its clinical pipeline, which

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Thu, 18 Jun 2026 08:00:00 -0400

Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases
Denali was awarded Priority Review Voucher following FDA approval of AVLAYAH™, the first FDA-approved biologic specifically designed to cross blood-brain barrier

SOUTH SAN FRANCISCO, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. The U.S. Food and Drug Administration (FDA) awarded the PRV to Denali

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Thu, 18 Jun 2026 08:00:00 -0400

Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases
Denali was awarded Priority Review Voucher following FDA approval of AVLAYAH™, the first FDA-approved biologic specifically designed to cross blood-brain barrier

UBS Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Tue, 16 Jun 2026 09:27:15 -0400

UBS analyst Michael Yee reiterated a Buy rating and $25.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI).

The analyst commented, "The early launch of Avlayah is progressing with positive signals on early launch indicators. Commercial product was in the channels 2 weeks from the March 24 approval with the earliest Hunter patients on drug in 3.5 weeks in the commercial setting and co is working through getting policies in place with positive receptivity from payers who recognise this is a premium product vs. standard of care Elaprase and thus priced at a ~60% premium to Elaprase which does not treat

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Krognes Steve E.